Key Highlights
- Loss per share was USD 0.73 against an estimate of a USD 0.76 loss.
- Collaboration Revenue was USD 1.91 million against an estimate of USD 1.90 million.
- Net loss was USD 94.88 million, against USD 110.75 million a year earlier.
- Total operating expenses were USD 100.98 million, against USD 117.36 million.
Alumis (NASDAQ:ALMS) reported a third quarter 2026 loss per share of USD 0.73, against an estimate of a USD 0.76 loss and a USD 1.06 loss in the third quarter of 2025. Collaboration revenue was USD 1.91 million, against an estimate of USD 1.90 million.
Net loss was USD 94.88 million, compared with USD 110.75 million. The loss from operations was USD 99.08 million, compared with USD 115.29 million.
Operating Expenses
Total operating expenses were USD 100.98 million, compared with USD 117.36 million. General and administrative expenses were USD 20.19 million, compared with USD 19.52 million. The filing states that other Research and Development costs increased by USD 4.1 million to USD 5.7 million, primarily due to increased preclinical research activities supporting development programs and the research pipeline, while facilities and overhead costs decreased by USD 0.6 million to USD 6.1 million.
Nine-Month Results
For the nine months ended September 30, 2026, net loss was USD 330.16 million, compared with USD 150.39 million, and the loss per share was USD 2.59, compared with USD 1.92. Total operating expenses were USD 351.65 million, compared with USD 379.48 million, and the loss from operations was USD 346.34 million, compared with USD 357.36 million.
General and administrative expenses for the nine months were USD 62.16 million, compared with USD 76.27 million. The nine-month figures include an intangible Assets Impairment loss of USD 41.82 million, with none in the prior-year period.
Liquidity and Agreements
The filing states that the company's primary uses of cash are to fund operations, which consist primarily of research and development expenditures related to its programs, and to a lesser extent, general and administrative expenditures. It notes that net cash provided by investing activities for the nine months ended September 30, 2025 of USD 192.9 million was related to proceeds from maturities of marketable securities of USD 305.4 million and cash, cash equivalents and restricted cash acquired in connection with the ACELYRIN Merger of USD 49.7 million.
Total current assets were USD 442.59 million, compared with USD 318.23 million at the prior Balance Sheet date. Deferred revenue, current, was USD 6.88 million, compared with USD 1.46 million.
The filing describes a services agreement with Foresite Labs entered into in January 2021, which expires in December 2026 unless terminated earlier, and operating leases for approximately 55,000 square feet of office and laboratory space in South San Francisco, California, commencing in January 2023, and approximately 22,000 square feet of additional space under a Lease entered into in December 2024.
The balance sheet reports total assets of USD 488.71 million, total liabilities of USD 110.29 million, an accumulated Deficit of USD 1,232.03 million and total stockholders' Equity of USD 378.43 million. For the nine months, net cash used in Operating Activities was USD 248.15 million and net cash provided by financing activities was USD 367.23 million.
Alumis Q3 2026 Earnings: Key Takeaways
Alumis reported a third quarter 2026 loss per share of USD 0.73 and a net loss of USD 94.88 million. Total operating expenses were USD 100.98 million, compared with USD 117.36 million a year earlier.
_11_16_2026_19_56_26_124029.jpg)





Please wait processing your request...